Approach
Pipeline & Portfolio
View pipeline
GRWD
5769
Pipeline
About
Publications
News
News
View Pipeline
Scientific posters
Careers
Contact
Latest news
Stay updated with our latest insights and breakthroughs
All
Feature
Press releases
In the media
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Category
Press releases
Greywolf Therapeutics reports durable clinical responses with first-in-class oral ERAP1 inhibitor GRWD5769 across six solid tumor types
Read more
View all
News
Media features
Events
Press releases
GWT completes £10m ($14m) series A financing
Read more
Press releases
GWT completes £10m ($14m) series A financing
Read more
Previous
Discover how our therapies are reshaping treatment for various diseases and conditions.
Our approach
Harnessing antigen modulation to empower T cells against diseases.
Latest news
Cookie Policy
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our
Privacy Policy
for more information.
Decline
Accept